Biopharmaceutical company SAB Biotherapeutics (SAB) said on Tuesday that it has entered into a multiple research collaboration and option agreement with CSL Behring to treat challenging autoimmune, infectious and idiopathic diseases.
The partnership will share the research programme and related costs and plan to complete the initial phase in 2020. The collaboration may lead to subsequent development and commercialization agreements.
CSL Behring, a biotherapeutics company, will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB's DiversitAb platform. SAB has developed a unique platform, through advanced genetic engineering, to naturally and rapidly produce large amounts of human antibodies without using human donors.
Under the research programme, the companies will investigate a potential new source for human immunoglobulin G (IgG) used for immunological and neurological diseases including Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP) and Multifocal Motor Neuropathy (MMN).
In addition, CSL Behring's R&D footprint includes more than 1,700 scientists across the globe with an R&D investment exceeding USD800m in 2018 - 2019.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007